Investigation of arterial obstruction using a mercury-in-rubber strain gauge

Holling, H. E.; Boland, Helena; Russ, E. M.

doi:10.1016/0002-8703(61)90318-0

Cited by 94 publications

(32 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Strain gauge venous occlusion plethysmography, a well-known and highly accurate method for the study of small arterioles (27), was used to study forearm blood flow. These studies were performed using a strain gauge plethysmograph (model EC5R; Hokanson, Bellevue, WA).…”

Section: Methodsmentioning

confidence: 99%

Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis

Sfikakis¹,

Papamichael

Stamatelopoulos

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. Increased endothelin activity may play a role in the pathogenesis of vascular injury, a primary feature of systemic sclerosis (SSc; scleroderma). Our goal was to test the hypothesis that treatment with the oral endothelin receptor antagonist bosentan might improve vascular endothelial function in SSc patients.Methods. A 4-week, prospective, parallel-group study compared 12 SSc patients who did not receive bosentan treatment with 12 patients who did receive treatment (125 mg/day) for pulmonary hypertension and/or digital ulcers. There were no differences in demographic and clinical characteristics or medications between the 2 groups. Baseline endothelial dysfunction was documented by decreased brachial artery ultrasound-derived flow-mediated dilation (FMD%; <5.5). Pulse wave analysis, venous occlusion plethysmography, and measurement of serum vascular markers were performed in parallel.Results. FMD%, the main end point, increased significantly from a mean ؎ SD of 3.1 ؎ 1.3% to 8.4 ؎ 2.6% after 4 weeks of bosentan treatment (P < 0.001, compared with a change from 2.4 ؎ 1.6% to 2.4 ؎ 2.2% in control patients). Arterial blood pressure, endothelium-independent vascular function, augmentation index, peripheral flow reserve, as well as circulating intercellular adhesion molecule 1, E-selectin, vascular endothelial growth factor, and endothelin 1 were not significantly affected by bosentan treatment. In patients continuously treated for 4 months, during which the dosage of bosentan remained at 125 mg/day (n ‫؍‬ 5) or increased to 250 mg/day (n ‫؍‬ 5), the 4-week results remained unchanged.Conclusion. Small doses of bosentan improve endothelial function without affecting hemodynamic parameters or endothelial activation-related processes, thus supporting a direct, reversible effect of endothelin in SSc-associated vascular injury. A long-term, controlled trial to examine the potentially global clinical benefit of endothelin receptor blockade in patients with early SSc may be warranted.

show abstract

Section: Methodsmentioning

confidence: 99%

Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis

Sfikakis¹,

Papamichael

Stamatelopoulos

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…Forearm blood flow was measured by the venous occlusion technique with a single-strand mecury-in-rubber strain gauge plethysmograph as previously described (24,(31)(32)(33). A 20-gauge Teflon intra-arterial needle was inserted in the contralateral radial artery for the measurement of systemic blood pressure, and forearm vascular resistance was calculated.…”

Section: Evaluation Of Arteriolar Tonementioning

confidence: 99%

“…We specifically did not want to induce venodilation or arteriolar dilation by having the subjects in a warm environment (23). A single strand mercury-inrubber strain gauge (24) was utilized for measurements of forearm venous tone and blood flow as described below. It was balanced with a Wheatstone's bridge (Parks Electronics Laboratory, Beaverton, Ore.) and was calibrated by stretching to known percents of resting lengths at 10 g of tension.…”

Section: Introductionmentioning

confidence: 99%

The Cardiovascular Effects of Morphine THE PERIPHERAL CAPACITANCE AND RESISTANCE VESSELS IN HUMAN SUBJECTS

Zelis¹,

Mansour²,

Capone³

et al. 1974

J. Clin. Invest.

142

View full text Add to dashboard Cite

“…The PRHBF has been repeatedly demonstrated to be lowered in patients with peripheral vascular disease, even though the basal blood flow usually is normal (10)(11)(12)(13)). An ischemic stimulus presumably dilates the arterioles sufficiently so that the caliber of the larger arteries, i.e.…”

Section: Discussionmentioning

confidence: 99%

“…Since population studies have thus far yielded equivocal results (7)(8)(9), it was considered desirable to examine the response of a specific vascular bed to treatment designed to lower blood lipids. In view of the difficulties inherent in measuring serial changes in the coronary circulation, it was our plan to study the vasculature of the extremities, in which the functional evaluation is simple, atraumatic, and accurate (10)(11)(12)(13)(14). Patients with well defined lipid abnormalities from the National Institutes of Health registry of familial hyperlipoproteinemias were selected for this study (15,16).…”

mentioning

confidence: 99%

Effects of hyperlipoproteinemias and their treatment on the peripheral circulation

Zelis¹,

Mason²,

Braunwald³

et al. 1970

J. Clin. Invest.

133

View full text Add to dashboard Cite

A B S T R A C T The purpose of this study was to determine the effect of familial hyperlipoproteinemia (HLP) on peripheral vascular disease (PVD) and the extent to which the vascular disease is modified by treatment of the lipoprotein disorder. PVD was detected plethysmographically by observing a diminished peak reactive hyperemia blood (PRHBF) following ischemia. The value for PRHBF in the extremity demonstrating the lowest response in 32 normal subjects (age 19-50 yr) was 39.6 ±1.5 SEM, ml/min per 100 g. Patients with untreated HLP, who had PRHBF below the lower limit of normal, were 2 of 11 type II, 9 of 12 type III, 1 of 10 type IV. As a group, patients with type III HLP showed diminished PRHBF (26.6 ±3.0 ml/min per 100 g, P < 0.01). In view of the high incidence of PVD and the striking reduction in serum lipids and complete resorption of xanthomas observed in type III HLP with therapy, six patients were studied before and after 3-6 months of treatment with a therapeutic diet and clofibrate. PRHBF in the most severely affected extremity increased markedly, from 20.4 ±1.6 to 31.9 ±1.8 ml/min per 100 g (P < 0.01), indicating a dramatic increase in maximum blood flow to this extremity. In two type III patients with PVD not treated, no change in PRHBF occurred over 5 months. In two other type III patients the PRHBF increased 17% during the first 25 days of therapy concomitant with a 30% reduction in whole blood viscosity. Over the next 120 days, blood viscosity decreased only an additional 4.6% whereas the PRHBF increased 57%, indicating that the observed changes seen in the PRHBF with therapy of type III patients can be only

show abstract

Investigation of arterial obstruction using a mercury-in-rubber strain gauge

Cited by 94 publications

References 12 publications

Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis

Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis

The Cardiovascular Effects of Morphine THE PERIPHERAL CAPACITANCE AND RESISTANCE VESSELS IN HUMAN SUBJECTS

Effects of hyperlipoproteinemias and their treatment on the peripheral circulation

Contact Info

Product

Resources

About